

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/915,060		07/25/2001	Sigrid Cornelis	4976US	6077
24247	7590	10/30/2003		EXAMINER	
TRASK B	RITT		SULLIVAN, DANIEL M		
P.O. BOX 2	2550				
SALT LAK	SALT LAKE CITY, UT 84110			ART UNIT	PAPER NUMBER
				1636	
				D. (TE) () () () () () () () () ()	_

DATE MAILED: 10/30/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
Advisory Action	09/915,060	CORNELIS ET AL.
Advisory Action	Examiner	Art Unit
	Daniel M Sullivan	1636
The MAILING DATE of this communication app	pears on the cover sheet with the	correspondence address
THE REPLY FILED 07 October 2003 FAILS TO PLACE Therefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may only be either: (condition for allowance; (2) a timely filed Notice of Appe Examination (RCE) in compliance with 37 CFR 1.114.	avoid abandonment of this application 1) a timely filed amendment which	cation. A proper reply to a chaptaces the application in
	REPLY [check either a) or b)]	
a) The period for reply expiresmonths from the mail b) The period for reply expires on: (1) the mailing date of this no event, however, will the statutory period for reply expire ONLY CHECK THIS BOX WHEN THE FIRST REPLY WA 706.07(f).	s Advisory Action, or (2) the date set forth a later than SIX MONTHS from the mailin AS FILED WITHIN TWO MONTHS OF T	ng date of the final rejection. HE FINAL REJECTION. See MPEP
Extensions of time may be obtained under 37 CFR 1.136(a). The ee have been filed is the date for purposes of determining the period ee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of 2) as set forth in (b) above, if checked. Any reply received by the Of imely filed, may reduce any earned patent term adjustment. See 37	t of extension and the corresponding am of the shortened statutory period for reply ffice later than three months after the ma	ount of the fee. The appropriate extension originally set in the final Office action; or
1. A Notice of Appeal was filed on Appellant 37 CFR 1.192(a), or any extension thereof (37 CF		
2. The proposed amendment(s) will not be entered to	because:	
(a) 🛛 they raise new issues that would require furth	ner consideration and/or search ((see NOTE below);
(b) 🖂 they raise the issue of new matter (see Note	below);	
(c) they are not deemed to place the application issues for appeal; and/or	in better form for appeal by mate	erially reducing or simplifying the
(d) they present additional claims without cance	eling a corresponding number of	finally rejected claims.
NOTE: <u>See Continuation Sheet</u> .		
3. Applicant's reply has overcome the following rejection	ction(s):	
 Newly proposed or amended claim(s) would canceling the non-allowable claim(s). 	d be allowable if submitted in a s	eparate, timely filed amendment
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because:		idered but does NOT place the
6. The affidavit or exhibit will NOT be considered be raised by the Examiner in the final rejection.	cause it is not directed SOLELY	to issues which were newly
7. For purposes of Appeal, the proposed amendmer explanation of how the new or amended claims were appeared to the proposed amendment.		
The status of the claim(s) is (or will be) as follows		
Claim(s) allowed:		
Claim(s) objected to:		
Claim(s) rejected: 4,11 15,23-25 and 27-40.		
Claim(s) withdrawn from consideration:		
8. \square The proposed drawing correction filed on $___$ is	s a) ☐ approved or b) ☐ disapp	proved by the Examiner.
9. \square Note the attached Information Disclosure Stateme	ent(s)(PTO-1449) Paper No(s)	
0. Other:		Tavel Jugo
		PHIMARY EXAMINER
		•

Application No. 09/915,060

Continuation of 2. NOTE: The proposed amendments limit the nucleic acid of claims 4 and 25, and claims depending therefrom, to a chimeric nucleic acid molecule consisting of a nucleic acid sequence selected from various disclosed sequences. However, the sequences set forth in the application as SEQ ID NO: 1 and 4-7 are not disclosed as being chimeric. Thus, the proposed amendments raise new issues under 35 U.S.C. §112, second paragraph.

The proposed amendments limit the nucleic acid of claim 37, and claims depending therefrom, to a recombinant nucleic acid molecule consisting of SEQ ID NO:1, 4-6 or 7 comprised within a chimeric nucleic acid molecule. First, Applicant has not indicated where the originally filed specification teaches a nucleic acid having the limitations of claim 37, and the Examiner is unable to find the nucleic acid of claim 37 in the original disclosure. Therefore, the proposed amendment raises the issue of new matter. Furthermore, it is not clear whether claim 37 is directed only to the nucleic acid molecule consisting of SEQ ID NO: 1, 4-6 or 7, which is comprised within a chimeric nucleic acid molecule, or whether the claim is directed to the entire chimeric nucleic acid molecule, which comprises a nucleic acid consisting of SEQ ID NO: 1, 4-6 or 7..